Olgotrelvir: meta-analysis of COVID-19 studies

All studies   Hospitalization   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
Meta-analysis1 study · 1K patientsc19early.org

Olgotrelvir for COVID-19

Serious outcome risk
Olgotrelvir
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)67%
Hospitalization (1)67%
RCTs (1)67%
Early (1)67%
00.511.5+
← Olgotrelvir
reduces riskIncreased
risk →
c19early.org
October 2026

Olgotrelvir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)67%0.33 · 0.01–8.18oxygen0/6041/608MPR-COV-301CN
Early treatment67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →
c19early.org
October 2026

Olgotrelvir COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)67%0.33 · 0.01–8.18hosp.0/6041/608MPR-COV-301CN
Early treatment67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →
c19early.org
October 2026

Olgotrelvir COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)67%0.33 · 0.01–8.18oxygen0/6041/608MPR-COV-301CN
Early treatment67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →
c19early.org
October 2026

Olgotrelvir COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)22%0.78 · 0.68–0.89no recov.604 (n)608 (n)MPR-COV-301CN
Early treatment22%0.78 · 0.68–0.88604 (n)608 (n)22% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.00011
All studies22%0.78 · 0.68–0.88604 (n)608 (n)22% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0001100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →
c19early.org
October 2026

Olgotrelvir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)67%0.33 · 0.01–8.18oxygen0/6041/608MPR-COV-301CN
Early treatment67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →
c19early.org
October 2026

Olgotrelvir COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jiang (DB RCT)67%0.33 · 0.01–8.18oxygen0/6041/608MPR-COV-301CN
Early treatment67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies67%0.33 · 0.01–8.180/6041/60867% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Olgotrelvir
reduces riskOlgotrelvir
increases risk →